Segall Bryant & Hamill LLC Has $6.75 Million Stake in Integra Lifesciences Holdings Corp (IART)

Segall Bryant & Hamill LLC grew its position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 12.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 149,737 shares of the life sciences company’s stock after purchasing an additional 16,021 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.18% of Integra Lifesciences worth $6,753,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. Cardinal Capital Management increased its holdings in shares of Integra Lifesciences by 1.6% during the fourth quarter. Cardinal Capital Management now owns 17,899 shares of the life sciences company’s stock valued at $807,000 after acquiring an additional 287 shares in the last quarter. Swiss National Bank grew its holdings in Integra Lifesciences by 12.2% during the third quarter. Swiss National Bank now owns 130,294 shares of the life sciences company’s stock worth $8,582,000 after buying an additional 14,200 shares in the last quarter. We Are One Seven LLC grew its holdings in Integra Lifesciences by 41.3% during the fourth quarter. We Are One Seven LLC now owns 4,546 shares of the life sciences company’s stock worth $205,000 after buying an additional 1,328 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Integra Lifesciences by 104.2% during the third quarter. JPMorgan Chase & Co. now owns 277,064 shares of the life sciences company’s stock worth $18,251,000 after buying an additional 141,368 shares in the last quarter. Finally, Blueshift Asset Management LLC bought a new stake in Integra Lifesciences during the fourth quarter worth $230,000. 83.89% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages recently issued reports on IART. Cantor Fitzgerald reiterated a “hold” rating and set a $50.00 price target on shares of Integra Lifesciences in a report on Thursday, February 21st. ValuEngine upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Wednesday, February 13th. Oppenheimer reissued a “buy” rating on shares of Integra Lifesciences in a research report on Tuesday, March 19th. Zacks Investment Research raised Integra Lifesciences from a “sell” rating to a “hold” rating in a research report on Monday, February 18th. Finally, Morgan Stanley set a $57.00 price objective on Integra Lifesciences and gave the stock a “hold” rating in a research report on Friday, February 22nd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the stock. Integra Lifesciences has a consensus rating of “Hold” and an average target price of $60.67.

Shares of NASDAQ IART traded down $0.13 during trading on Monday, reaching $53.71. 190,203 shares of the stock traded hands, compared to its average volume of 466,476. Integra Lifesciences Holdings Corp has a 52-week low of $42.14 and a 52-week high of $67.50. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.95 and a quick ratio of 1.88. The stock has a market capitalization of $4.60 billion, a PE ratio of 22.19, a P/E/G ratio of 1.59 and a beta of 0.96.

Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings results on Thursday, February 21st. The life sciences company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.03. Integra Lifesciences had a return on equity of 16.02% and a net margin of 4.13%. The firm had revenue of $383.30 million for the quarter, compared to analysts’ expectations of $382.33 million. During the same quarter in the prior year, the firm earned $0.64 EPS. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. As a group, equities analysts expect that Integra Lifesciences Holdings Corp will post 2.68 EPS for the current fiscal year.

In other Integra Lifesciences news, Director Rhonda Germany Ballintyn bought 1,933 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were acquired at an average cost of $56.08 per share, for a total transaction of $108,402.64. Following the purchase, the director now directly owns 3,665 shares of the company’s stock, valued at $205,533.20. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Richard E. Caruso sold 30,128 shares of the company’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $56.06, for a total value of $1,688,975.68. Following the completion of the transaction, the insider now owns 143,384 shares in the company, valued at $8,038,107.04. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Segall Bryant & Hamill LLC Has $6.75 Million Stake in Integra Lifesciences Holdings Corp (IART)” was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.baseballdailydigest.com/news/2019/04/15/integra-lifesciences-holdings-corp-iart-shares-bought-by-segall-bryant-hamill-llc.html.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Recommended Story: What is the Current Ratio?

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.